On September 22, Ionis Pharmaceuticals rose 7.15% in pre-market trading, trading at $47.19/share, with turnover of $455,700. The rally was driven by the company announcing positive topline results from the Phase 3 Fusion study of its investigational drug Ulefnersen in FUS gene mutation-associated amyotrophic lateral sclerosis (FUS-ALS).

Ulefnersen, an antisense oligonucleotide therapy designed to target the root cause of FUS-ALS, demonstrated statistically significant and clinically meaningful improvement on the primary endpoint. This milestone positions Ulefnersen as the first potential disease-modifying therapy for FUS-ALS, a currently unmet medical need. The company plans to present detailed data at upcoming medical conferences and engage with regulators on the path forward.

The positive readout follows a challenging period for Ionis. In July, its cardiovascular pipeline suffered a setback when the Phase 3 Cardio-Ttransform trial of eplontersen in ATTR-CM failed to meet its primary endpoint, prompting multiple analyst target price cuts and a sharp stock decline. More recently, on September 4, the FDA approved Ionis's Zanvastro (zilganersen) for Alexander disease, and in June, Tryngolza received FDA approval for severe hypertriglyceridemia, reinforcing the company's RNA-targeted therapeutic platform.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)